With Oral Wegovy in the Gulf and Medicare on the Horizon, Novo Nordisk Awaits Its Pipeline Verdict
04.06.2026 - 15:13:16 | boerse-global.de
Novo Nordisk is entering one of its most consequential stretches in years, juggling an international rollout of its oral weight-loss pill, a landmark expansion of US government coverage, and a make-or-break clinical data readout that could determine the trajectory of its pipeline beyond the current GLP-1 blockbusters. The Danish drugmaker’s stock has lost roughly 17% year-to-date and more than 41% over the past twelve months, closing Thursday at €36.90 after edging up 1.37% on the day. By Wednesday’s close, the decline had been even steeper at 18.54% and 42.64% respectively, underscoring the erosion in investor confidence that the coming weeks will test.
The immediate commercial catalyst is the launch of the Wegovy pill in the United Arab Emirates – the first market outside the US to receive the oral formulation. Novo Nordisk announced the availability on Wednesday, tapping a country where nearly 28% of adults live with obesity and where the affected population is projected to reach 7.5 million by 2035. The approval rests on the OASIS-4 program, in which patients taking a daily 25 mg dose of semaglutide achieved an average weight loss of about 17%, and one in three participants shed at least 20% of their starting weight. The pill also carries a cardiovascular benefit: it is the only approved oral obesity drug in both the UAE and the US that also lowers the risk of heart attack and stroke. European approval remains pending, though the European Medicines Agency has issued a positive opinion, with a final decision expected in the coming months.
On the reimbursement front, a separate shift is gathering momentum in the United States. Starting July 1, eligible Medicare beneficiaries with obesity will gain access to Wegovy – both the injectable and the oral tablet – for a monthly copay of $50. This marks a significant break from the past, when a federal ban had prevented Medicare from covering prescription drugs specifically for weight management. Novo Nordisk and rival Eli Lilly have agreed to a net monthly price of $245, far below the list prices of more than $1,000. The program runs until the end of 2027 and could bring millions of new patients into the market, but the muted net pricing highlights the fundamental tension facing the entire obesity therapy space: expanding volume at the cost of compressed margins. Novo Nordisk’s full-year guidance already reflects this pressure, with revenue and operating profit expected to decline by 5% to 13% in 2026, driven by lower realized US prices, reduced Medicaid reimbursements, and the impact of most-favored-nation pricing agreements.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The next big test for the pipeline comes at the American Diabetes Association’s Scientific Sessions in New Orleans from June 5 to 8. Novo Nordisk will present 40 abstracts, headlined by Phase 3 results from the REIMAGINE program for CagriSema – a weekly injection combining cagrilintide and semaglutide. The data will show how the combination therapy improves blood sugar control and weight loss in patients with type 2 diabetes, and they will be closely watched as a measure of Novo Nordisk’s ability to keep pace with Eli Lilly in the GLP-1 arms race. An R&D investor meeting is scheduled for June 7 at 18:30 local time. CagriSema was submitted to the US Food and Drug Administration in December 2025, with a decision expected in the fourth quarter of 2026 and a potential commercial launch in early 2027. Also on the program are Phase 2b data for Zenagamtid, a dual GLP-1 and amylin receptor agonist, and new evidence on Ozempic and Wegovy in cardiometabolic diseases.
First-quarter results released earlier this year illustrate why new markets and pipeline progress are so urgent. Adjusted group revenue slid 4% to around 70 billion Danish kroner, while operating profit fell 6%. The obesity business bucked the trend with 22% growth, and the Wegovy pill alone generated 2.3 billion kroner in its first full quarter on the US market, backed by more than two million prescriptions. The UAE launch is a logical next step to replicate that momentum outside the United States, and Europe remains the most important outstanding catalyst on the regulatory calendar.
On the technical side, the stock’s recent trading offers a mixed picture. The share price has crept back above its 50-day moving average of €35.68, suggesting the worst of the rout may be over. But it remains well below the 200-day line of €41.72, and the gap to the 52-week high of roughly €70 stands at nearly 47%. Novo Nordisk has also been buying back its own shares, with a program of up to 15 billion Danish kroner that began on February 4. As of May 29, the company had repurchased 17.89 million B-shares for a total of 4.71 billion kroner.
The converging events – a Gulf market debut, an imminent Medicare shift, and a critical pipeline data readout – give Novo Nordisk multiple levers to rebuild investor trust. But each comes with its own risks: the commercial launches face pricing constraints, the clinical results must be unequivocally positive to counter the threat from competitors, and the broader financial outlook remains under pressure from patent expirations on older semaglutide formulations in several international markets. The next few weeks will show whether the company can turn these pieces into a coherent story of growth, or whether the headwinds will continue to drag on its valuation.
Ad
Novo Nordisk Stock: New Analysis - 4 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
